Mirtazapine belongs to a class of medications called tetracyclic antidepressants, though in clinical practice it is more precisely described as a noradrenergic and specific serotonergic antidepressant, or NaSSA. That classification matters because mirtazapine works through a mechanism that has almost nothing in common with the SSRIs most people are familiar with. It does not block the reuptake of serotonin or norepinephrine the way most modern antidepressants do, and this difference explains many of its distinctive traits, from its sedating effects at low doses to its tendency to stimulate appetite.
How Mirtazapine Actually Works
The “tetracyclic” label refers to the drug’s molecular shape: four fused rings, as opposed to the three rings of older tricyclic antidepressants like amitriptyline. But the shape alone does not tell you much about what the drug does in the brain. What makes mirtazapine distinctive is how it boosts serotonin and norepinephrine without blocking their reuptake.
Mirtazapine’s primary action is blocking alpha-2 adrenergic receptors. These receptors normally act as a brake on both norepinephrine and serotonin release. By blocking them, mirtazapine essentially takes the foot off the brake, allowing more of both neurotransmitters to flow. This is why it was described as disinhibiting both serotonin and norepinephrine neurotransmission when it was approved.1Journal of Clinical Psychiatry. Development of new antidepressants
But mirtazapine does not simply flood the brain with serotonin the way SSRIs do. It simultaneously blocks certain serotonin receptor subtypes, specifically 5-HT2 and 5-HT3 receptors, while allowing serotonin to act primarily through 5-HT1A receptors.2Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Mirtazapine: An Antidepressant with Noradrenergic and Specific Serotonergic Effects This selective serotonin routing is the “specific” in “noradrenergic and specific serotonergic antidepressant.” It matters clinically because many of the side effects people associate with SSRIs, such as sexual dysfunction and nausea, are thought to be driven by stimulation of 5-HT2 and 5-HT3 receptors. Mirtazapine blocks those receptors rather than activating them, which is a big part of why its side effect profile looks so different from an SSRI’s.
On top of all this, mirtazapine is also a strong blocker of histamine H1 receptors, which accounts for its most immediately noticeable effect: sedation.3PubMed Central. Tachyphylaxis to the Sedative Action of Mirtazapine This mix of receptor actions is why mirtazapine does not fit neatly into the SSRI or tricyclic boxes. It is its own thing, and the NaSSA classification was created largely to describe it.
Why Lower Doses Are More Sedating
One of the most counterintuitive things about mirtazapine is that people often feel drowsier on the starting dose of 15 mg than on higher doses like 30 or 45 mg. This seems backward, but it has a pharmacological explanation. At low doses, the histamine-blocking effect dominates because the H1 receptor has very high affinity for the drug. As the dose increases, more norepinephrine-boosting activity kicks in through alpha-2 receptor blockade, and that additional noradrenergic drive counteracts the sedation. Clinicians sometimes describe this as mirtazapine’s sedation being “dose-inversely related,” meaning that going up in dose can actually make someone feel less sleepy.
An FDA adverse-event analysis explored whether higher doses were associated with more adrenergic side effects like agitation, insomnia, and anxiety. After reviewing over 14,000 adverse reaction reports and analyzing 308 qualifying cases, the researchers found no association between mirtazapine dose and the likelihood of these adrenergic effects.4PubMed Central. Relationship between mirtazapine dose and incidence of adrenergic side effects: An exploratory analysis So while higher doses counteract the sedation, they do not reliably trigger the opposite extreme either. The practical takeaway is that if sedation is a problem at 15 mg, increasing the dose rather than stopping the drug is sometimes the first adjustment a prescriber tries.
Effects on Sleep
Because mirtazapine is so sedating, it is frequently prescribed off-label for insomnia and sleep difficulties, particularly when those problems accompany depression. But its effects on sleep go beyond simple drowsiness. Studies using polysomnography, which tracks brain activity throughout the night, show that mirtazapine increases slow-wave sleep, the deepest and most restorative phase. In depressed patients, mirtazapine increased total slow-wave sleep and the amount of slow-wave sleep in the first sleep cycle.5PubMed. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine That same study found that REM sleep latency (the time before dreaming sleep begins) increased, while the number of REM episodes decreased.
A separate pilot study in depressed patients, however, found that mirtazapine did not significantly alter REM sleep parameters.6PubMed. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study The discrepancy likely reflects differences in study size and duration. What both studies agree on is that mirtazapine improves sleep continuity and does not suppress REM the way many other antidepressants do. SSRIs and tricyclics are known for dramatically reducing REM sleep, which can affect dream recall and subjective sleep quality. Mirtazapine’s relative gentleness toward REM architecture is one reason sleep specialists sometimes favor it over other antidepressants when insomnia is a major concern.
Faster Onset Than SSRIs
One of the more compelling findings about mirtazapine is that it appears to start working sooner than SSRIs. This is clinically significant because the standard timeline for antidepressant response, typically two to four weeks, is agonizing for someone in a depressive episode. A Cochrane systematic review pooling 29 randomized controlled trials with nearly 5,000 participants found that mirtazapine was significantly more effective than SSRIs at the two-week mark. It also showed a modest edge over SSRIs at the end of acute-phase treatment over six to twelve weeks.7Cochrane Database of Systematic Reviews. Mirtazapine versus other antidepressive agents for depression
A meta-analysis of individual patient data from 15 controlled trials quantified the early advantage more precisely: mirtazapine-treated patients had roughly 74% higher odds of achieving remission during the first two weeks compared to those on SSRIs. The remission rate gap narrowed over time but remained statistically significant at six weeks.8PubMed. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression A pooled analysis of three earlier trials found that about 13% of mirtazapine patients showed persistent improvement in the first week versus 6% of those on SSRIs, though the researchers cautioned this was a retrospective observation.9PubMed. Does mirtazapine have a more rapid onset than SSRIs?
It is worth noting that faster onset does not necessarily mean better long-term outcomes. Some of mirtazapine’s early perceived improvement may reflect the immediate effects on sleep and anxiety rather than a faster antidepressant mechanism per se. Still, when someone is severely depressed and struggling to function, even a one- to two-week head start matters a great deal.
Appetite, Weight Gain, and Metabolic Effects
Weight gain is probably the side effect most closely associated with mirtazapine, and it is a real concern that keeps some prescribers and patients away from the drug. The mechanism involves several of the receptors mirtazapine blocks. Histamine H1 antagonism increases appetite in general, while inverse agonism at 5-HT2C receptors is thought to specifically drive cravings for carbohydrates and sweets.
A controlled study in healthy men found that mirtazapine increased hunger and appetite for sweets and shifted energy metabolism toward preferring carbohydrates as a fuel source. The drug also increased insulin and C-peptide release after a standardized meal, suggesting it alters how the body processes carbohydrates at a metabolic level.10PubMed Central. Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men Interestingly, that study did not observe significant weight gain during its short duration, nor did it find changes in resting energy expenditure, indicating that mirtazapine drives weight gain primarily by making people eat more rather than by slowing their metabolism.
For some patients, this side effect is actually the reason mirtazapine is chosen. Depression often comes with appetite loss and unintended weight loss, and a drug that simultaneously treats the mood disorder and restores appetite can be exactly what is needed. In geriatric settings especially, where malnutrition is a serious concern, mirtazapine’s appetite-stimulating effect is sometimes a feature rather than a bug.
Safety in Overdose
Mirtazapine has a relatively favorable safety profile compared to older antidepressants, especially tricyclics, which can cause lethal cardiac arrhythmias in overdose. Two studies examining mirtazapine overdose specifically found minimal cardiac risk. One retrospective review of 29 patients admitted to a toxicology unit after mirtazapine overdose, at an average dose of 594 mg, found no significant QT prolongation. A larger observational case series of 267 overdose cases, including 89 single-agent ingestions, also found no reports of arrhythmias or QT prolongation.11InpharmD. What Class Is Mirtazapine? Tetracyclic Antidepressant Explained
One pharmacoepidemiological study did flag a statistically significant association between mirtazapine and sudden death or ventricular arrhythmia compared to paroxetine, but the researchers themselves noted that baseline health differences between the groups likely explained the finding.12PubMed Central. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia In general, mirtazapine is considered one of the safer antidepressants in overdose, which is a relevant consideration when prescribing to someone who may be at risk for a suicide attempt.
Drug Metabolism and Interactions
Mirtazapine is broken down in the liver by multiple enzyme pathways, primarily CYP2D6, CYP1A2, and CYP3A4. The fact that several enzymes share the workload is actually protective: if one pathway is inhibited or genetically underactive, the others can pick up the slack. Laboratory studies confirmed that mirtazapine itself does not substantially inhibit any of these major liver enzymes, meaning it is unlikely to raise blood levels of other drugs you might be taking.13Drug Metabolism and Disposition. Metabolism of the Antidepressant Mirtazapine in Vitro: Contribution of Cytochromes P-450 1A2, 2D6, and 3A4
That said, mirtazapine’s own blood levels can be affected by other medications. CYP2D6 is the primary enzyme responsible for one of mirtazapine’s main metabolic pathways. People who are genetically poor metabolizers of CYP2D6, or who take drugs that strongly inhibit it, can end up with meaningfully higher mirtazapine concentrations. A study in Japanese patients found that CYP2D6 poor and intermediate metabolizers had significantly higher mirtazapine plasma levels per dose. The common medications risperidone and duloxetine, both CYP2D6 inhibitors that might be co-prescribed with mirtazapine, also reduced mirtazapine clearance in liver microsomes.14PubMed. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients For most people the multi-enzyme safety net means interactions are moderate, but anyone combining mirtazapine with strong inhibitors of CYP2D6, CYP3A4, or CYP1A2 should expect the possibility of increased sedation and other dose-related effects.
Mirtazapine for Anxiety Disorders
Although mirtazapine is approved for depression, its receptor profile makes it a plausible candidate for anxiety disorders, and it is used off-label for generalized anxiety, social anxiety, and post-traumatic stress disorder. A recent systematic review and meta-analysis evaluated the existing evidence across these conditions. For generalized anxiety disorder, mirtazapine performed on par with SSRIs and benzodiazepines. In depressed patients with significant anxiety symptoms, mirtazapine slightly outperformed SSRIs for anxiety reduction and matched tricyclic antidepressants. For PTSD, the evidence supported its use as an augmentation strategy alongside SSRIs. Patients’ willingness to stay on the drug was comparable to both placebo and SSRIs, suggesting it is reasonably well tolerated.15PubMed. Clinical Potential of Mirtazapine in Anxiety and Trauma-Related Disorders: A Systematic Review and Meta-Analysis of Current Evidence
The anxiety-reducing effect probably comes from the same receptor blockade that distinguishes mirtazapine’s mechanism. The 5-HT2 and 5-HT3 receptors it blocks are implicated in anxiety-like responses to serotonin. By channeling serotonin activity toward 5-HT1A receptors, which are associated with anxiolytic effects, mirtazapine achieves something like a cleaner serotonergic signal for mood and anxiety without the initial worsening of anxiety that some people experience when starting an SSRI.
Pregnancy and Breastfeeding
Data on mirtazapine in pregnancy are limited but generally reassuring. A systematic review examining 390 exposed neonates across 31 papers found no increased risk of major congenital malformations associated with mirtazapine use during pregnancy. There was a possible association with spontaneous abortion, but the reviewers could not separate this from the effects of the underlying psychiatric illness itself.16PubMed. Mirtazapine in pregnancy and lactation – A systematic review One study noted a near-significant increase in respiratory problems and low blood sugar in newborns, but no causal link could be established.
A more recent systematic review reached broadly similar conclusions: outcomes in mirtazapine-exposed pregnancies were generally comparable to controls, though results on malformations and spontaneous abortion were conflicting across studies. The review noted that neonatal adaptation syndrome, a cluster of temporary symptoms like irritability and feeding difficulty, was reported after late-pregnancy exposure.17PubMed Central. Mirtazapine in pregnancy and lactation: A systematic review of adverse outcomes Limited data on breastfeeding suggest low infant exposure through breast milk, though the evidence base is small. No information exists on long-term neurodevelopmental outcomes beyond the first year. The evidence is thin enough that any decision about mirtazapine during pregnancy involves weighing uncertain but probably small drug risks against the well-documented risks of untreated depression.
Tapering Off Mirtazapine
Mirtazapine is not considered one of the hardest antidepressants to stop, but withdrawal symptoms can still occur, including rebound insomnia, anxiety, nausea, and irritability. A recent pharmacokinetic modeling study examined a common tapering shortcut used for various antidepressants: switching to alternate-day dosing instead of gradually reducing the daily dose. The analysis found that skipping days caused large swings in receptor occupancy, and these swings worsened as the dose dropped. The researchers concluded that increasing the interval between doses at minimum therapeutic levels likely increases withdrawal risk and cannot be recommended as a safe tapering strategy.18PubMed. Alternate-day dosing to taper antidepressants risks severe withdrawal effects: an in silico analysis The preferred approach is gradual dose reduction, ideally using smaller dose increments than are available in standard tablet sizes, which sometimes means splitting tablets or using liquid formulations.
The “California Rocket Fuel” Combination
Mirtazapine’s unique mechanism makes it a natural complement to reuptake-blocking antidepressants, because the two approaches boost neurotransmitter activity through entirely different routes. The combination of mirtazapine with venlafaxine (an SNRI) has acquired the colloquial name “California Rocket Fuel” in psychiatric practice and is one of the more commonly used strategies for treatment-resistant depression. Preclinical research found that combining sub-effective doses of mirtazapine and venlafaxine produced an antidepressant effect that neither drug achieved alone at those doses, while the combination did not impair sexual behavior in the animal model tested.19PubMed. The combination of mirtazapine plus venlafaxine reduces immobility in the forced swim test and does not inhibit female sexual behavior The sexual-function finding is of particular interest because sexual side effects are among the most common reasons patients stop antidepressant therapy.
In clinical practice, combining mirtazapine with an SSRI or SNRI is a well-established augmentation strategy. Mirtazapine’s 5-HT2 and 5-HT3 blockade can blunt some of the side effects caused by the increased serotonin from the other drug, while its noradrenergic boost adds a second therapeutic dimension. The combination is not free of downsides: the additive sedation and weight gain can be significant. But for people who have not responded to multiple trials of single antidepressants, the combination offers a pharmacologically rational next step.
Mirtazapine in Veterinary Medicine
One of the more unexpected chapters in mirtazapine’s story is its widespread use in cats. Veterinarians routinely prescribe it as an appetite stimulant for cats with chronic kidney disease, cancer, and other conditions that cause weight loss and food refusal. In 2018, a transdermal ointment formulation of mirtazapine became the first FDA-approved weight-gain drug specifically for cats.
A placebo-controlled trial of the transdermal ointment in cats with unintended weight loss found that treated cats gained an average of about 3.9% of body weight, compared to 0.4% in the placebo group, a highly significant difference. The ointment, applied to the inner ear flap, was well tolerated both at the application site and systemically.20PubMed Central. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss In cats with chronic kidney disease specifically, compounded transdermal mirtazapine at both 3.75 mg and 1.88 mg doses produced significant weight gain and increased appetite, with over half the cats showing improved body condition scores.21PubMed Central. Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease
A survey of cat owners using transdermal mirtazapine found that about 77% considered it effective at stimulating appetite, with roughly 40% of those owners noticing improvement within the first 24 hours.22PubMed Central. Owner’s Perspective About the Use of Mirtazapine Transdermal Ointment in Cats—A Survey-Based Study The drug works in cats through the same histamine and serotonin receptor mechanisms that cause appetite increase in humans. For a drug whose weight-gain side effect is often a liability in human patients, finding a population where that exact effect is desperately needed is a satisfying bit of pharmacological recycling.
Mirtazapine in Older Adults
Mirtazapine has particular relevance in geriatric psychiatry. Older adults with depression often struggle with insomnia, appetite loss, and weight loss simultaneously. A drug that addresses all three while carrying a lower risk of the anticholinergic effects common to tricyclics and a lower risk of the falls associated with SSRIs can be a natural fit. A small open-label pilot study in patients with Alzheimer’s disease tested mirtazapine for agitation and found that the most common early side effects were sedation, fatigue, and dizziness, mostly at the 15 mg starting dose. One patient who was too sedated at 15 mg actually tolerated 30 mg without sedation, consistent with the inverse dose-sedation pattern described above. No significant weight gain or changes in cognitive test scores were observed over the 12-week study.23PubMed Central. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study
The absence of strong anticholinergic effects is worth emphasizing. Older tricyclic antidepressants block acetylcholine receptors, which can cause dry mouth, constipation, urinary retention, confusion, and falls. These effects are dangerous in older adults and can worsen cognitive impairment. Mirtazapine has only moderate muscarinic receptor activity, making it a substantially safer choice for this population. Orthostatic hypotension (dizziness on standing) can still occur, as the pilot study noted, but serious cardiac complications are uncommon.